AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16 (cancelled).

17 (currently amended). A pharmaceutical and/or veterinary solid implant formulation comprising about 2-15% (w/w) of at least one GnRH agonist peptide (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin, wherein said GnRH agonist peptide is other than deslorelin.

18 (currently amended). A formulation according to claim 17, comprising about 5-10% (w/w) of the GnRH agonist peptide (on an active basis), about 0.5-1.5% (w/w) lecithin and about 89-94% (w/w) stearin.

19 (currently amended). A formulation according to claim 18, comprising about 5% (w/w) of the GnRH agonist peptide (on an active basis), 1% (w/w) lecithin and the 94% (w/w) stearin.

20 (currently amended). A formulation according to claim 18, comprising about 5% (w/w) of the GnRH agonist peptide (on an active basis), 2% (w/w) lecithin and 93% (w/w) stearin.

21 (cancelled).

22 (previously presented). A formulation according to claim 17, wherein the lecithin and stearin are in non-crystalline form.

23 (previously presented). A method of treating a disease or condition in an animal for which suppression of sex hormone levels is beneficial, the method comprising administering to the animal an effective amount of the formulation of claim 17 to ameliorate said disease or condition.

24 (previously presented). A method according to claim 23, wherein the disease or condition is selected from the group consisting of prostate cancer, ovarian and breast cancer, endometriosis, myoma, premenstrual tension, uterine fibroids, hirsutism, cyclic auditory dysfunction, prophyria and precocious puberty.

25 (previously presented). A method according to claim 23, wherein the lecithin and stearin are in non-crystalline form.

26 (previously presented). A method of preventing reproductive function from functioning in an animal, the method comprising administering to the animal the formulation of claim 17.

27 (previously presented). A method according to claim 25, wherein the lecithin and stearin are in non-crystalline form.

28 (previously presented). A method of treating benign prostatic hyperplasia in an animal, the method comprising administering to the animal the formulation of claim 17, whereby treating the benign prostatic hyperplasia.

29 (previously presented). A method according to claim 28, wherein the animal being treated is a dog.

30 (previously presented). A method according to claim 28, wherein the lecithin and stearin are in non-crystalline form.